TGF-β signaling has been implicated in EMT of prostate cancer cells, which, in turn, has been implicated in treatment related neuroendocrine differentiation and therapeutic resistance to androgen deprivation therapy and radiotherapy [17]. This evidence concerns the gene TGFB1 and prostate cancer.